HomeAbout MBIBiomedical Division

Biomedical Division

Biomedical Division
  Due to the growing medical demand initiated by the aging population and sedentary life style, MBI’s biomedical division has utilized its core competence in biopolymers, such as collagen and hyaluronic acid, and developed a broad range of medical devices for orthopedic, ophthalmic, dental and surgical applications.  Our biomedical products have received market approval and certification for Taiwan, China, USA, Europe, Southeast Asia, Middle East and other emerging markets.  In addition, our orthopedic product, Formagraft®, has been acquired by Nasdaq-listed medical device company – NuVasive Inc. in 2007.  NuVasive also made equity investment in MBI in the same year and became one of our strategic partners.  MBI's Biomedical facility is certified by Taiwan GMP/ISO13485/Korean KGMP and has also passed FDA inspection in 2009 and 2015.